HUALAN BIOLOGICAL VACCINE INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 21.28 CNY | -8.87% |
|
-6.13% | -23.45% |
| 04-25 | Hualan Biological Vaccine Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 04-01 | Hualan Biological Vaccine Inc. Proposes Final Cash Dividend for 2023 | CI |
| Sales 2024 * | 2.93B 405M 32.4B | Sales 2025 * | 3.56B 491M 39.36B | Capitalization | 12.77B 1.76B 141B |
|---|---|---|---|---|---|
| Net income 2024 * | 1.04B 143M 11.45B | Net income 2025 * | 1.28B 177M 14.18B | EV / Sales 2024 * | 4.36 x |
| Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 3.59 x |
| P/E ratio 2024 * |
12.3
x | P/E ratio 2025 * |
9.96
x | Employees | 770 |
| Yield 2024 * |
3.34% | Yield 2025 * |
3.95% | Free-Float | 13.86% |
More Fundamentals
* Assessed data
More news
| 1 day | -8.87% | ||
| 1 week | -6.13% | ||
| Current month | -10.89% | ||
| 1 month | -9.52% | ||
| 3 months | -11.66% | ||
| 6 months | -23.73% | ||
| Current year | -23.45% |
1 week
20.73
23.54
1 month
20.7324.57
Current year
19.1627.93
1 year
19.1636.50
3 years
19.1653.19
5 years
19.1653.19
10 years
19.1653.19
| Managers | Title | Age | Since |
|---|---|---|---|
Wen Jue An
CEO | Chief Executive Officer | 35 | 28/03/22 |
Cheng Yu Lü
DFI | Director of Finance/CFO | 43 | 31/05/20 |
Xiao Feng Cui
CTO | Chief Tech/Sci/R&D Officer | 49 | 31/03/17 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Kang An
CHM | Chairman | 75 | 31/03/13 |
Bei Fan
BRD | Director/Board Member | 52 | 31/03/13 |
Ruo Wen Pan
BRD | Director/Board Member | 56 | 31/05/13 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 21.28 | -8.87% | 9,825,559 |
| 25/04/24 | 23.35 | +1.17% | 2,336,800 |
| 24/04/24 | 23.08 | -1.03% | 1,949,108 |
| 23/04/24 | 23.32 | +1.00% | 2,306,634 |
| 22/04/24 | 23.09 | +1.85% | 2,163,052 |
End-of-day quote Shenzhen S.E., April 25, 2024
More quotes
Hualan Biological Vaccine Inc, formerly Hualan Biological Bacterin Inc, is a China-based company principally engaged in the research, development, production and sales of human vaccines. The Company's listed products mainly include influenza virus split vaccine, quadrivalent influenza virus split vaccine, influenza A H1N1 split vaccine, recombinant hepatitis B vaccine and others. The Company's products that have been approved for clinical trials or have passed clinical registration and are pending for marketing mainly include human rabies vaccines, adsorbed tetanus vaccines, H7N9 influenza whole virus inactivated vaccines and others. The Company's products in the preclinical research stage include inactivated new coronavirus vaccine, freeze-dried nasal spray recombinant new coronavirus live attenuated vaccine and others.
Sector
Pharmaceuticals
Calendar
20/08/2024
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
21.28
CNY
Average target price
33.2
CNY
Spread / Average Target
+56.02%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -23.45% | 1.76B | |
| -4.66% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -16.09% | 15.35B | |
| -9.14% | 11.95B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| +5.24% | 8.71B |
- Stock Market
- Equities
- 301207 Stock
